SN-38 overcomes chemoresistance of colorectal cancer cells induced by hypoxia, through HIF1alpha

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 865-872

  Murono, Koji ^a   Tsuno, Nelson H ^a   Kawai, Kazushige ^a   Sasaki, Kazuhito ^a   Hongo, Kumiko ^a   Kaneko, Manabu ^a   Hiyoshi, Masaya ^a   Tada, Noriko ^a   Nirei, Takako ^a   Sunami, Eiji ^a   Takahashi, Koki ^a   Kitayama, Joji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Colorectal cancer; Hypoxia; Hypoxia inducible factor; Irinotecan; SN 38

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXALIPLATIN;

ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE G0 PHASE; CELL HYPOXIA; CHEMOSENSITIVITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CELL CYCLE; CELL DIVISION; CELL HYPOXIA; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUOROURACIL; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; ORGANOPLATINUM COMPOUNDS;

EID: 84863352583     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Harris AL: Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
2. Primeau AJ, Rendon A, Hedley D, Lilge L and Tannock IF: The distribution of the anticancer drug doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 11: 8782-8788, 2005. (Pubitemid 43005929)
3. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
4. Ogawa K, Chiba I, Morioka T, Shimoji H, Tamaki W, Takamatsu R, Nishimaki T, Yoshimi N and Murayama S: Clinical significance of HIF-1alpha expression in patients with esophageal cancer treated with concurrent chemoradiotherapy. Anticancer Res 31: 2351-2359, 2011.
5. Semenza GL: Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 12: 853-859, 2007.
6. Cao D, Hou M, Guan YS, Jiang M, Yang Y and Gou HF: Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer 9: doi: 10.1186/1471-2407-9-432, 2009.
7. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS and Ogino S: HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 176: 2292-2301, 2010.
8. Kwon HC, Kim SH, Oh SY, Lee S, Kwon KA, Choi HJ, Park KJ, Kim HJ and Roh MS: Clinicopathological significance of p53, hypoxia-inducible factor 1alpha, and vascular endothelial growth factor expression in colorectal cancer. Anticancer Res 30: 4163-4168, 2010.
9. Rasheed S, Harris AL, Tekkis PP, Turley H, Silver A, McDonald PJ, Talbot IC, Glynne-Jones R, Northover JM and Guenther T: Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer 100: 1666-1673, 2009.
10. Korkeila EA, Sundstrom J, Pyrhonen S and Syrjanen K: Carbonic anhydrase IX, hypoxia-inducible factor-1alpha, ezrin and glucose transporter-1 as predictors of disease outcome in rectal cancer: multivariate Cox survival models following data reduction by principal component analysis of the clinicopathological predictors. Anticancer Res 31: 4529-4535, 2011.
11. Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C, Stratford IJ, and Dive C: Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24: 2875-2889, 2004. (Pubitemid 38381277)
12. Yoshiba S, Ito D, Nagumo T, Shirota T, Hatori M and Shintani S: Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. Oral Oncol 45: 109-115, 2009.
13. Huang L, Ao Q, Zhang Q, Yang X, Xing H, Li F, Chen G, Zhou J, Wang S, Xu G, Meng L, Lu Y and Ma D: Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha. J Cancer Res Clin Oncol 136: 447-456, 2010.
14. Ban HS, Uno M and Nakamura H: Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: Different profiles of AAL993 versus SU5416 and KRN633. Cancer Lett 296: 17-26, 2010.
15. Chia JS, Du JL, Hsu WB, Sun A, Chiang CP and Wang WB: Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid. BMC Cancer 10: doi: 10.1186/1471-2407-10-175, 2010.
16. El-Khatib M, Geara F, Haddadin MJ, and Gali-Muhtasib H: Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21. Radiat Oncol 5: doi: 10.1186/1748-717X-5-107, 2010.
17. Lee K, Kang JE, Park SK, Jin Y, Chung KS, Kim HM, Kang MR, Lee MK, Song KB, Yang EG, Lee JJ and Won M: LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1alpha via up-regulation of VHL in a colon cancer cell line. Biochem Pharmacol 80: 982-989, 2010.
18. Melillo G: Targeting hypoxia cell signaling for cancer therapy. Cancer Metastasis Rev 26: 341-352, 2007.
19. Su W, Huang L, Ao Q, Zhang Q, Tian X, Fang Y and Lu Y: Noscapine sensitizes chemoresistant ovarian cancer cells to cisplatin through inhibition of HIF-1alpha. Cancer Lett 305: 94-99, 2011.
20. Shiau AL, Shen YT, Hsieh JL, Wu CL and Lee CH: Scutellaria barbata inhibits angiogenesis through downregulation of HIF-1 alpha in lung tumor. Environ Toxicol doi: 10.1002/tox.21763, 2012.
21. Palayoor ST, Tofilon PJ and Coleman CN: Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res 9: 3150-3157, 2003. (Pubitemid 37006311)
22. Del Bufalo D, Ciuffreda L, Trisciuoglio D, Desideri M, Cognetti F, Zupi G and Milella M: Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66: 5549-5554, 2006. (Pubitemid 43927103)
23. Li X and Fan Z: The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 70: 5942-5952, 2010.
24. 2 availability on human cancer. Nat Rev Cancer 8: 967-975, 2008.
25. Bhuyan BK, Blowers CL, Neil GL, Bono VH and Day KJ: Partial synchronization of L1210 cells by 5-fluorouracil and its use in drug combinations. Cancer Res 37: 3204-3208, 1977. (Pubitemid 8169979)
26. Galvez-Peralta M, Dai NT, Loegering DA, Flatten KS, Safgren SL, Wagner JM, Ames MM, Karnitz LM and Kaufmann SH: Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10- hydroxycamptothecin (SN-38) in human carcinoma cell lines. Mol Pharmacol 74: 724-735, 2008.
27. Wallin A, Svanvik J, Holmlund B, Ferreud L and Sun XF: Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Oncol Rep 19: 1493-1498, 2008.
28. Arango D, Wilson AJ, Shi Q, Corner GA, Aranes MJ, Nicholas C, Lesser M, Mariadason JM and Augenlicht LH: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91: 1931-1946, 2004. (Pubitemid 40065523)
29. Wen W, Ding J, Sun W, Wu K, Ning B, Gong W, He G, Huang S, Ding X, Yin P, Chen L, Liu Q, Xie W and Wang H: Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res 70: 2010-2019, 2010.
30. Sasabe E, Zhou X, Li D, Oku N, Yamamoto T and Osaki T: The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer 120: 268-277, 2007. (Pubitemid 44956835)
31. Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC and El-Deiry WS: Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Res 71: 5265-5275, 2011.
32. Gardner LB, Li Q, Park MS, Flanagan WM, Semenza GL and Dang CV: Hypoxia inhibits G-1/S transition through regulation of p27 expression. J Biol Chem 276: 7919-7926, 2001.
33. Green SL, Freiberg RA and Giaccia AJ: p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol Cell Biol 21: 1196-1206, 2001. (Pubitemid 32114968)
34. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH and Melillo G: Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 64: 1475-1482, 2004. (Pubitemid 38235619)
35. Kamiyama H, Takano S, Tsuboi K and Matsumura A: Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells. J Cancer Res Clin Oncol 131: 205-213, 2005. (Pubitemid 40238935)
36. Takano S, Kamiyama H, Mashiko R, Osuka S, Ishikawa E and Matsumura A: Metronomic treatment of malignant glioma xenografts with irinotecan (CPT-11) inhibits angiogenesis and tumor growth. J Neurooncol 99: 177-185, 2010.
37. Pencreach E, Guerin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP and Guenot D: Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res 15: 1297-1307, 2009.
38. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
39. Jansen WJ, Zwart B, Hulscher ST, Giaccone G, Pinedo HM and Boven E: CPT-11 in human colon cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 70: 335-340, 1997. (Pubitemid 27099604)